Tag: steatohepatitis

April 1, 2019 Off

Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH

The Phase 2a program will include two separate studies Phase 2a efficacy and safety study for PXL770 is underway with…

January 23, 2019 Off

Second Genome doses first patients in second phase testing SGM-1019

Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH).